CN107137422A - 植物果胶在治疗痛风症制品中的应用 - Google Patents
植物果胶在治疗痛风症制品中的应用 Download PDFInfo
- Publication number
- CN107137422A CN107137422A CN201710425926.9A CN201710425926A CN107137422A CN 107137422 A CN107137422 A CN 107137422A CN 201710425926 A CN201710425926 A CN 201710425926A CN 107137422 A CN107137422 A CN 107137422A
- Authority
- CN
- China
- Prior art keywords
- pectin
- plant
- gout
- application
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001814 pectin Substances 0.000 title claims abstract description 70
- 229920001277 pectin Polymers 0.000 title claims abstract description 70
- 235000010987 pectin Nutrition 0.000 title claims abstract description 70
- 201000005569 Gout Diseases 0.000 title claims abstract description 40
- 238000011282 treatment Methods 0.000 title claims abstract description 39
- 241000196324 Embryophyta Species 0.000 claims abstract description 35
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 27
- 235000009566 rice Nutrition 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 12
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 12
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000007884 disintegrant Substances 0.000 claims abstract description 10
- 239000000314 lubricant Substances 0.000 claims abstract description 10
- 239000000945 filler Substances 0.000 claims abstract description 9
- 240000007594 Oryza sativa Species 0.000 claims abstract 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 150000004676 glycans Chemical class 0.000 claims description 15
- 229920001282 polysaccharide Polymers 0.000 claims description 15
- 239000005017 polysaccharide Substances 0.000 claims description 15
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 241001327634 Agaricus blazei Species 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- 239000011812 mixed powder Substances 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 244000020551 Helianthus annuus Species 0.000 claims description 6
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 244000099147 Ananas comosus Species 0.000 claims description 5
- 235000007119 Ananas comosus Nutrition 0.000 claims description 5
- 244000276331 Citrus maxima Species 0.000 claims description 5
- 235000001759 Citrus maxima Nutrition 0.000 claims description 5
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 4
- 241000335053 Beta vulgaris Species 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 235000004936 Bromus mango Nutrition 0.000 claims description 2
- 241000207199 Citrus Species 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 240000007228 Mangifera indica Species 0.000 claims description 2
- 235000014826 Mangifera indica Nutrition 0.000 claims description 2
- 235000009184 Spondias indica Nutrition 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 235000020971 citrus fruits Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 229960002708 antigout preparations Drugs 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 241000209094 Oryza Species 0.000 description 23
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 20
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 19
- 229940116269 uric acid Drugs 0.000 description 19
- 235000011430 Malus pumila Nutrition 0.000 description 7
- 235000015103 Malus silvestris Nutrition 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000009194 citrus pectin Substances 0.000 description 5
- 229940040387 citrus pectin Drugs 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000007968 uric acids Chemical class 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 229920000018 Callose Polymers 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- -1 methoxyl group Chemical group 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了植物果胶在治疗痛风症制品中的应用。本发明还提供了植物果胶片剂制品及其制备方法,包括植物果胶、麦芽糖糊精、超微稻壳粉、填充剂、崩解剂、润滑剂。本发明制备的果胶片剂形成一类新的具有治疗痛风作用的组合物,为痛风患者的治疗开辟了新的方向。制备该治疗痛风的组合物的原料均可用于食品,无副作用,制备方法简单易行,便于工业化生产。该植物果胶片剂一种辅料量小、果胶分散均匀、片剂崩解性好、片剂稳定性好、生物利用度高的能有效治疗痛风的片剂。本发明提供了果胶在制备抗高尿酸血症和抗痛风保健食品中的应用,扩大了抗高尿酸血症和抗痛风药物或保健食品的资源范围。
Description
技术领域
本发明属于天然活性成分提取以及应用领域,具体涉及植物果胶制品,及植物果胶在治疗痛风症制品中的应用。
背景技术
痛风是一组嘌呤代谢紊乱所致的疾病,其临床特点为高尿酸血症及由此而引起的痛风性急性关节炎反复发作、痛风石沉积、痛风石性慢性关节炎和关节畸形,常累及肾脏,引起慢性间质性肾炎和尿酸肾结石形成。痛风可分原发性和继发性两大类。原发性痛风指在排除其他疾病的基础上,由于先天性嘌呤代谢紊乱和(或)尿酸***障碍所引起;原发性者少数由于酶缺陷引起,常伴高脂血症、肥胖、糖尿病、高血压病、动脉硬化和冠心病等。继发性者可由肾脏病、血液病及药物等多种原因引起。
当血中尿酸浓度长期高于7.8 毫克/100C.C,医学上就称为“高尿酸血症”。血中尿酸会因为尿酸的产量过多而***减少而升高,引起尿酸产量过多的原因包括先天性代谢异常、淋巴增生疾病等,这些原因占引起高尿酸血症的百分之十左右。而引至尿酸***减少的原因则包括肾功能障碍和药物引起的不良尿酸***。高尿酸血症是引起痛风的主因。研究指出在男性身上,血尿酸浓度愈高者,出现痛风症状的机会愈高。
现代医学对痛风的治疗方法多以消炎止痛、促进尿酸盐***、降低血尿酸为主。目前,对于痛风与高尿酸血症的常规治疗仍以西药为主,西医治疗痛风的药物为抗炎药和降尿酸药两大类。这些药物以不同的途径能够达到缓解或治疗痛风与高尿酸血症的目的,但通过临床观察发现,此类药物对胃肠道、肝脏、肾脏功能有损害,毒副作用大,不能依赖性服用;若病人长期服用,可导致骨髓抑制,肝细胞坏死,神经性反应和胃肠道不良反应。
果胶是人类自然饮食的一部分,一般从柑橘皮、苹果皮、葡萄皮、蚕砂和甜菜渣等植物细胞中提取。果胶的80%~90%用于食品工业,利用其凝胶性生产胶冻、果酱和软糖。还可用在医药方面作止血剂和***,也可用来治疗腹泻和重金属中毒等。果胶是羟基被不同程度甲酯化的线性聚半乳糖醛酸和聚L-鼠李糖半乳糖醛酸,其是 FAO/WHO 食品添加剂联合委员会推荐的安全无毒的天然食品添加剂,且无每日添加量限制。
发明内容
本发明的目的是提供一种植物果胶在治疗痛风症制品中的应用,并提供该制品的一种产品形式以及生产方式。
果胶是一种由D-半乳糖醛酸通过α-(1-4)糖苷键与半乳糖、鼠李糖和***糖等中性糖连接并聚合而形成的高分子多糖。苹果果胶含有部分甲氧基和乙酰基,具有一般果胶的结构;苹果果胶中除半乳糖醛酸外含有8种单糖,鼠李糖、岩藻糖、果糖、***糖、木糖、甘露糖、葡萄糖和半乳糖。柑橘果胶是一种以半乳糖为主要成分的多糖,分子量小,无抗原性,水溶性好;柑橘果胶中有鼠李糖、***糖、木糖、葡萄糖和半乳糖,柑橘皮中果胶含量为30%-35% 。柚皮,特别是白皮层中果胶含量特别高。甜菜渣中果胶含量为16%-21%,因其分子量相对低,存在乙酸酯化,并且有大量的中性糖侧链,影响了甜菜渣果胶的内在质量稍差于柑橘果胶或苹果果胶。向日葵盘的果胶含量为17%-25%,其半乳糖醛酸含量为66%-80%;向日葵盘果胶具有典型的低甲氧基果胶特征。菠萝皮果胶含有乙酰基且为低酯果胶,含有鼠李糖、***糖、木糖、甘露糖、葡萄糖及半乳糖,以木糖及半乳糖居多。
为达到上述目的,本发明采取的具体技术方案为:
植物果胶在治疗痛风症制品中的应用。
进一步的,所述植物果胶包括但不限于苹果、柑橘、柚子、菠萝、芒果、向日葵、甜菜等中提取得到的果胶的一种或多种混合。
利用上述果胶制得治疗痛风症的制品,包括保健品、药品等。
其中,上述植物果胶制品为片剂制品,包括植物果胶、麦芽糖糊精、超微稻壳粉、填充剂、崩解剂、润滑剂,各成分的重量份数为:
植物果胶 200-1000;麦芽糖糊精 30-70;超微稻壳粉 1-20;填充剂 2-20;崩解剂 5-40;润滑剂 5 -40。
进一步的,上述植物果胶片剂制品中还包括,以重量份数计,姬松茸多糖 1-5。
进一步的,所述填充剂为淀粉,或者淀粉与乳糖、木糖醇、山梨醇中的一种或多种的组合。
进一步的,所述填充剂为淀粉。
进一步的,所述的崩解剂为微晶纤维素、羧甲基淀粉钠、聚维酮中的一种或多种。
进一步的,所述崩解剂为微晶纤维素。
进一步的,所述润滑剂为硬脂酸镁、硬脂酸、二氧化硅的一种或多种混合。
进一步的,所述润滑剂为二氧化硅和硬脂酸镁,所述二氧化硅和硬脂酸镁的重量份数为:二氧化硅 2-10;硬脂酸镁 3-10。
上述植物果胶片剂制品的制备方法,包括如下步骤如下:
以重量份数计,将植物果胶 200-1000;麦芽糖糊精 30-70;填充剂 2-20;崩解剂 5-40;润滑剂 5 -40,过100目筛,备用;
以重量份数计,将超微稻壳粉 1-20,边研磨边加入a)中所述原料粉,充分混匀;
将b)中混匀的混合粉过100目筛,于1-10 KN压力下压片,即得到具有治疗痛风效果的植物果胶片剂制品。
进一步的,上述步骤a)中还包括以重量份数计,姬松茸多糖 1-5。
本发明的优点和技术效果:
果胶是一种天然的植物多糖,主要是一类以D-半乳糖醛酸(D-Galacturonic Acids,D-Gal-A)由α-1,4-糖苷键连接组成的酸性杂多糖,具有复杂的三维分子结构,有较强的生物活性,可应用于食品、医药保健品和化妆品。姬松茸多糖是从姬松茸子实体中分离得到的活性多糖,是一种具有三维立体构型的β-D-葡聚糖聚合体,含少量结合蛋白,生物活性极强,能提高机体免疫能力,调节体内电解质平衡,协同果胶作用,有利于尿酸的代谢。
目前压片技术多采用干法压片和湿法压片,均需要先将原料制粒后再压片,其中制粒过程中部分原料黏在制粒设备上而损耗,制得颗粒筛分时,也有部分粒度不合适的原料损耗,加工工艺复杂,周期长且损耗偏大。超微稻壳粉是一种纳米级超微稻壳粉末,其粒度均匀,粒径为10 μm,经处理后形成一种可压性极高的可压性能,同时能提高果胶的可压性,与其他干燥辅料粉末混合后可直接压片,在1-10kN条件下即可成片,无需制粒,制得片剂崩解时间短,硬度适中,可大大缩短生产周期,提高效率,无原料损耗,降低生产成本。
本发明经过临床试验验证了,本发明提取制备的植物果胶能够有效降低病患尿酸含量,从而有效改善痛风症状。果胶可促进尿酸盐的***,降低血尿酸浓度,所以,果胶应用到治疗痛风症的制品中无毒副作用,可长期服用,并且具有良好疗效,具有很大优势及良好前景。
本发明制备的果胶片剂形成一类新的具有治疗痛风作用的组合物,为痛风患者的治疗开辟了新的方向。制备该治疗痛风的组合物的原料均可用于食品,因此,无副作用,制备方法简单易行,便于工业化生产。该植物果胶片剂一种辅料量小、果胶分散均匀、片剂崩解性好、片剂稳定性好、生物利用度高的能有效治疗痛风的片剂。本发明提供了果胶在制备抗高尿酸血症和抗痛风保健食品中的应用,扩大了抗高尿酸血症和抗痛风药物或保健食品的资源范围。
具体实施方式
下面结合具体实施例进一步解释和说明本发明。
实施例1:
各原料组分:苹果果胶 450 g;超微稻壳粉 50g;姬松茸多糖 2g;麦芽糖糊精 25 g;淀粉 5 g;微晶纤维素 10 g;二氧化硅 5 g;硬脂酸镁 5 g。
制法:
a) 称取处方量的原料(除超微稻壳粉)过100目筛,备用;
b) 称取处方量的超微稻壳粉,边研磨边加入a)中所述原料粉,充分混匀;
c) 将b)中混匀的混合粉过100目筛,于1-10 KN压力下压片,即得具有治疗痛风效果的苹果果胶片剂。
实施例2:
各原料组分:柑橘果胶 455 g;超微稻壳粉 15g;麦芽糖糊精 25 g;淀粉 5 g;微晶纤维素 15 g;硬脂酸镁 5 g。
制法:
a) 称取处方量的原料(除超微稻壳粉)过100目筛,备用;
b) 称取处方量的超微稻壳粉,边研磨边加入a)中所述原料粉,充分混匀;
c) 将b)中混匀的混合粉过100目筛,于1-10 KN压力下压片,即得具有治疗痛风效果的柑橘果胶片剂。
实施例3:
各原料组分:柚子果胶 454 g;超微稻壳粉 20g;麦芽糖糊精 25 g; 微晶纤维素 15 g;二氧化硅 1 g;硬脂酸镁 5 g。
制法:
a) 称取处方量的原料(除超微稻壳粉)过100目筛,备用;
b) 称取处方量的超微稻壳粉,边研磨边加入a)中所述原料粉,充分混匀;
c) 将b)中混匀的混合粉过100目筛,于1-10 KN压力下压片,即得具有治疗痛风效果的柚子果胶片剂。
实施例4:
各原料组分:甜菜果胶460 g;超微稻壳粉 41g;姬松茸多糖 4g;麦芽糖糊精 20 g ;微晶纤维素 15 g;硬脂酸镁 5 g。
制法:
a) 称取处方量的原料(除超微稻壳粉)过100目筛,备用;
b) 称取处方量的超微稻壳粉,边研磨边加入a)中所述原料粉,充分混匀;
c) 将b)中混匀的混合粉过100目筛,于1-10 KN压力下压片,即得具有治疗痛风效果的甜菜果胶片剂。
实施例5:
各原料组分:菠萝果胶 455 g;超微稻壳粉 32g;麦芽糖糊精 20 g;淀粉 5 g;微晶纤维素 10 g;二氧化硅 5 g;硬脂酸镁 5 g。
制法:
a) 称取处方量的原料(除超微稻壳粉)过100目筛,备用;
b) 称取处方量的超微稻壳粉,边研磨边加入a)中所述原料粉,充分混匀;
c) 将b)中混匀的混合粉过100目筛,于1-10 KN压力下压片,即得具有治疗痛风效果的菠萝果胶片剂。
实施例6:
各原料组分:向日葵果胶 465 g;超微稻壳粉 10g;姬松茸多糖 4g ;微晶纤维素 30g;硬脂酸镁5 g。
制法:
a) 称取处方量的原料(除超微稻壳粉)过100目筛,备用;
b) 称取处方量的超微稻壳粉,边研磨边加入a)中所述原料粉,充分混匀;
c) 将b)中混匀的混合粉过100目筛,于1-10 KN压力下压片,即得具有治疗痛风效果的向日葵果胶片剂。
试验验证:本发明提供的果胶片在痛风病人中的具体疗效。
实验方法:研究对象为从2016年1月至2016年10月在青岛某医院接受治疗的慢性痛风患者,共240例。年龄 30-60 岁,均为男性,符合痛风的诊断标准,无严重躯体疾病、酒精或药物依赖,无其他严重精神疾病。所有患者均签署知情同意书。
应用区组随机分组方法,病程相近的患者随机分入研究组和对照组。共8组,每组30 例,分为研究组食用实施例和对照组(对照组服用安慰片剂,服用量为每次3.0 g,每日2次 ,对照组1,服用添加了1%姬松茸多糖的安慰剂,服用量为每次3.0g,每日2次)。8组患者年龄、血尿酸水平等差异均无统计学意义 (P>0.05)。在治疗前及治疗2、4周后测定患者的血尿酸水平。
实验结果:研究组和对照组的血尿酸水平见表 1 所示。在治疗2、4周后,对照组与治疗前相比无明显差异;研究组与治疗前相比差异均有统计学意义,P<0.01。食用实施例的研究组,血尿酸明显降低,尤其在服用4周后已达正常范围内。说明此治疗痛风的组合物具有显著的治疗痛风的作用。同时,服用只添加姬松茸多糖的安慰剂的对照组1经过4周后,血尿酸含量比治疗前明显降低,效果比对照组显著,且实施例1、4和6组摄入样品中含植物果胶和姬松茸多糖,相比只含植物果胶的2、3和5组,其血尿酸降低水平更高,说明姬松茸多糖对植物果胶的降血尿酸效果有协同作用。
表 1. 研究组和对照组治疗前后血尿酸水平 ( ±S, μmol/L)
组别 | N | 治疗前 | 治疗2周 | 治疗4周 |
实施例1 | 30 | 514.22±86.44 | 444.62±71.86** | 371.95±69.43** |
实施例2 | 30 | 510.28±87.15 | 462.71±73.54** | 389.45±70.13** |
实施例3 | 30 | 513.22±84.31 | 465.22±74.31** | 380.13±69.77** |
实施例4 | 30 | 508.28±84.46 | 441.27±74.26** | 377.49±71.03** |
实施例5 | 30 | 504.22±87.45 | 462.68±70.06** | 382.05±71.14** |
实施例6 | 30 | 511.22±86.45 | 448.25±69.47** | 379.44±68.24** |
对照组 | 30 | 509.28±84.46 | 496.47±80.41 | 482.96±72.36 |
对照组1 | 30 | 510.45±84.23 | 488.36±77.89 | 445.13±75.96 |
**P<0.01 VS治疗前
以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (10)
1.植物果胶在治疗痛风症制品中的应用。
2.如权利要求1所述的应用,其特征在于,所述植物果胶包括由苹果、柑橘、柚子、菠萝、芒果、向日葵、甜菜等中提取得到的果胶的一种或多种混合。
3.如权利要求1所述的应用,其特征在于,利用所述植物果胶制得治疗痛风症的制品,包括保健品和药品,即为植物果胶制品。
4.如权利要求3所述的应用,其特征在于,所述植物果胶制片为片剂制品;包括植物果胶、麦芽糖糊精、超微稻壳粉、填充剂、崩解剂、润滑剂,各成分的重量份数为:植物果胶200-1000;麦芽糖糊精 30-70;超微稻壳粉 1-20;填充剂 2-20;崩解剂 5-40;润滑剂 5 -40。
5. 如权利要求4所述的应用,其特征在于,所述植物果胶片剂制品中还包括,以重量份数计,姬松茸多糖 1-5。
6.如权利要求4所述的应用,其特征在于,所述填充剂为淀粉,或者淀粉与乳糖、木糖醇、山梨醇中的一种或多种混合。
7.如权利要求4所述的应用,其特征在于,所述的崩解剂为微晶纤维素、羧甲基淀粉钠、聚维酮中的一种或多种。
8.如权利要求4所述的应用,其特征在于,所述润滑剂为硬脂酸镁、硬脂酸、二氧化硅的一种或多种混合。
9.权利要求4所述的植物果胶片剂制品的制备方法,其特征在于,包括如下步骤:
a) 以重量份数计,将植物果胶 200-1000;麦芽糖糊精 30-70;填充剂 2-20;崩解剂5-40;润滑剂 5 -40,过100目筛,备用;
b) 以重量份数计,将超微稻壳粉 1-20,边研磨边加入a)中所述原料粉,充分混匀;
c) 将b)中混匀的混合粉过100目筛,于1-10 KN压力下压片,即得到具有治疗痛风效果的植物果胶片剂制品。
10.如权利要求9所述的制备方法,其特征在于,上述步骤a)中还包括,以重量份数计,姬松茸多糖 1-5。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111445006.6A CN114344326A (zh) | 2017-06-08 | 2017-06-08 | 植物果胶在治疗痛风症的制品中的应用 |
CN201710425926.9A CN107137422A (zh) | 2017-06-08 | 2017-06-08 | 植物果胶在治疗痛风症制品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710425926.9A CN107137422A (zh) | 2017-06-08 | 2017-06-08 | 植物果胶在治疗痛风症制品中的应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111445006.6A Division CN114344326A (zh) | 2017-06-08 | 2017-06-08 | 植物果胶在治疗痛风症的制品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107137422A true CN107137422A (zh) | 2017-09-08 |
Family
ID=59780993
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710425926.9A Pending CN107137422A (zh) | 2017-06-08 | 2017-06-08 | 植物果胶在治疗痛风症制品中的应用 |
CN202111445006.6A Pending CN114344326A (zh) | 2017-06-08 | 2017-06-08 | 植物果胶在治疗痛风症的制品中的应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111445006.6A Pending CN114344326A (zh) | 2017-06-08 | 2017-06-08 | 植物果胶在治疗痛风症的制品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN107137422A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111467379A (zh) * | 2020-04-26 | 2020-07-31 | 苏州求是玉泉健康科技有限公司 | 一种甜菜提取物的制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1647695A (zh) * | 2004-12-14 | 2005-08-03 | 复旦大学 | 姬松茸水溶性多糖及其制备工艺和用途 |
CN104432309A (zh) * | 2014-11-13 | 2015-03-25 | 张�诚 | 一种缓解痛风的饮料及制作方法 |
CN105125610A (zh) * | 2015-09-16 | 2015-12-09 | 吉林大学 | 葵花盘水解复合粉剂在制备治疗或缓解高尿酸痛风症药物中的应用 |
CN105769848A (zh) * | 2016-03-28 | 2016-07-20 | 昆明医科大学 | 芒果苷元在制备防治慢性肾病药物和保健品中的应用 |
CN105902617A (zh) * | 2016-04-19 | 2016-08-31 | 王胜 | 一种用于缓解痛风的碱性植物盐及其制备方法 |
CN106261426A (zh) * | 2016-10-18 | 2017-01-04 | 浙江建设职业技术学院 | 一种用于降三高及尿酸的混合果蔬汁的制作方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102217745A (zh) * | 2011-05-06 | 2011-10-19 | 大连全植生物技术有限公司 | 一种天然植物酵素制剂 |
-
2017
- 2017-06-08 CN CN201710425926.9A patent/CN107137422A/zh active Pending
- 2017-06-08 CN CN202111445006.6A patent/CN114344326A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1647695A (zh) * | 2004-12-14 | 2005-08-03 | 复旦大学 | 姬松茸水溶性多糖及其制备工艺和用途 |
CN104432309A (zh) * | 2014-11-13 | 2015-03-25 | 张�诚 | 一种缓解痛风的饮料及制作方法 |
CN105125610A (zh) * | 2015-09-16 | 2015-12-09 | 吉林大学 | 葵花盘水解复合粉剂在制备治疗或缓解高尿酸痛风症药物中的应用 |
CN105769848A (zh) * | 2016-03-28 | 2016-07-20 | 昆明医科大学 | 芒果苷元在制备防治慢性肾病药物和保健品中的应用 |
CN105902617A (zh) * | 2016-04-19 | 2016-08-31 | 王胜 | 一种用于缓解痛风的碱性植物盐及其制备方法 |
CN106261426A (zh) * | 2016-10-18 | 2017-01-04 | 浙江建设职业技术学院 | 一种用于降三高及尿酸的混合果蔬汁的制作方法 |
Non-Patent Citations (6)
Title |
---|
ANG´ ELICA T. VIEIRA等: "Dietary fiber suppresses elevations of uric acid and allantoin in serum and urine induced by dietary RNA and increases its excretion to feces in rats.", 《JLB》 * |
TAKASHI KOGUCHI等: "Suppressive Effect of Viscous Dietary Fiber on Elevations of Uric Acid in Serum and Urine Induced by Dietary RNA in Rats is Associated with Strength of Viscosity", 《INT.J.VITAM.NUTR.RES.》 * |
卢丙俊: "苹果醋的加工", 《现代农业》 * |
周光兴: "《人类疾病动物模型复制方法学》", 31 January 2008 * |
姚如永: "《中西医结合实验技术》", 30 September 2013 * |
杨烁: "非布司他在高尿酸血症和慢性期痛风的疗效性及安全性分析", 《岭南急诊医学杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111467379A (zh) * | 2020-04-26 | 2020-07-31 | 苏州求是玉泉健康科技有限公司 | 一种甜菜提取物的制备方法和应用 |
CN111467379B (zh) * | 2020-04-26 | 2021-09-14 | 苏州承瑞健康科技有限公司 | 一种甜菜提取物的制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114344326A (zh) | 2022-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kalegowda et al. | Opuntia dillenii (Ker-Gawl) Haw cladode mucilage: Physico-chemical, rheological and functional behavior | |
Kumar et al. | Psyllium mucilage and its use in pharmaceutical field: an overview | |
Yu et al. | Immunomodulatory activities of sulfated Cyclocarya paliurus polysaccharides with different degrees of substitution on mouse spleen lymphocytes | |
CN109106944B (zh) | 一种预防和治疗骨关节炎的组合物及其应用 | |
US9694045B2 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same | |
CZ39699A3 (cs) | Směsi rostlinných uhlohydrátů jako potravinových doplňků | |
Kumar et al. | Pectin from fruit peels and its uses as pharmaceutical and food grade: a descriptive review | |
US20150030690A1 (en) | Prebiotic mixture | |
CN105030879A (zh) | 壳寡糖健骨保健品及其制备方法 | |
CN106262951A (zh) | 一种膳食纤维咀嚼片及其制备方法 | |
CN105770799A (zh) | 一种具有改善脑部记忆功能的颗粒制剂 | |
Gandhi et al. | Comparative study on effect of natural and synthetic superdisintegrants in the formulation of orodispersible tablets | |
Yadav et al. | Pectin as natural polymer: an overview | |
CN114271502A (zh) | 一种保护心血管***和肾脏的蛤蜊肽复合物及其应用 | |
CN101433332B (zh) | 改善肠道功能润肠通便的食品补充剂及其制备方法 | |
CN107137422A (zh) | 植物果胶在治疗痛风症制品中的应用 | |
CN1799411A (zh) | 具有润肠通便功能的膳食纤维组合物及其生产方法 | |
CN110881555A (zh) | 一种具有双降作用的分散糖果片 | |
Muruganantham et al. | Gums as Pharmaceutical Excipients: An Overview | |
CN108783448A (zh) | 一种肉苁蓉天麻复合咀嚼片配方及制备方法 | |
JP5903250B2 (ja) | 徐放性組成物 | |
JP2003048839A (ja) | 免疫反応性NO合成を誘導するiNOS酵素を刺激する組成剤およびその製造方法 | |
CA3026138C (en) | An edible composition for reducing the digestion or absorption of the harmful/toxic substance | |
WO2002015721A2 (de) | Zusammensetzungen zur nahrungsmittel- und tierfutterergänzung | |
Iswariya et al. | Natural super-Disintegrant agents used in various Oral solid dosage forms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170908 |